MedPath

Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy

Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma

Phase 3
Conditions
Neuroblastoma
First Posted Date
2006-01-13
Last Posted Date
2013-09-17
Lead Sponsor
Children's Cancer and Leukaemia Group
Registration Number
NCT00276731
Locations
🇬🇧

Institute of Child Health at University of Bristol, Bristol, England, United Kingdom

🇬🇧

Royal London Hospital, London, England, United Kingdom

🇬🇧

Sir James Spence Institute of Child Health, Newcastle-Upon-Tyne, England, United Kingdom

and more 18 locations

Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors

Not Applicable
Conditions
Brain and Central Nervous System Tumors
Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Ovarian Cancer
First Posted Date
2006-01-13
Last Posted Date
2013-09-17
Lead Sponsor
Children's Cancer and Leukaemia Group
Target Recruit Count
100
Registration Number
NCT00276718
Locations
🇮🇪

Our Lady's Hospital for Sick Children, Dublin, Ireland

🇬🇧

Great Ormond Street Hospital for Children NHS Trust, London, England, United Kingdom

🇬🇧

Birmingham Children's Hospital, Birmingham, England, United Kingdom

and more 18 locations

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2006-01-13
Last Posted Date
2010-08-09
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
46
Registration Number
NCT00276588
Locations
🇺🇸

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

Phase 1
Completed
Conditions
Breast
Cancer
First Posted Date
2006-01-13
Last Posted Date
2010-01-07
Lead Sponsor
University of New Mexico
Target Recruit Count
33
Registration Number
NCT00277069
Locations
🇺🇸

University of New Mexico, Albuquerque, New Mexico, United States

Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors

Phase 3
Conditions
Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Ovarian Cancer
First Posted Date
2006-01-11
Last Posted Date
2013-09-17
Lead Sponsor
Children's Cancer and Leukaemia Group
Target Recruit Count
105
Registration Number
NCT00274950
Locations
🇬🇧

Addenbrooke's Hospital, Cambridge, England, United Kingdom

🇬🇧

Birmingham Children's Hospital, Birmingham, England, United Kingdom

🇬🇧

Leicester Royal Infirmary, Leicester, England, United Kingdom

and more 16 locations

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
Interventions
First Posted Date
2006-01-11
Last Posted Date
2023-06-29
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
100
Registration Number
NCT00274924
Locations
🇺🇸

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

🇺🇸

Mason District Hospital, Havana, Illinois, United States

🇺🇸

Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States

and more 99 locations

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2006-01-02
Last Posted Date
2020-05-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
43
Registration Number
NCT00271505
Locations
🇺🇸

Lyndon Baines Johnson General Hospital, Houston, Texas, United States

🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)

Phase 2
Completed
Conditions
Head and Neck Cancer
Interventions
First Posted Date
2005-12-28
Last Posted Date
2017-02-01
Lead Sponsor
Mohan Suntharalingam
Target Recruit Count
21
Registration Number
NCT00270790
Locations
🇺🇸

University of Maryland, Baltimore, Maryland, United States

Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2005-12-23
Last Posted Date
2015-08-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
122
Registration Number
NCT00269152
Locations
🇪🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago De Compostela, Spain

Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery

Phase 2
Terminated
Conditions
Esophageal Cancer
Interventions
Drug: carboplatin
Drug: Pemetrexed
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: radiation therapy
First Posted Date
2005-12-22
Last Posted Date
2016-07-06
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
27
Registration Number
NCT00268437
Locations
🇺🇸

Rush-Copley Cancer Care Center, Aurora, Illinois, United States

🇺🇸

Graham Hospital, Canton, Illinois, United States

🇺🇸

Mason District Hospital, Havana, Illinois, United States

and more 87 locations
© Copyright 2025. All Rights Reserved by MedPath